|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
TWI598347B
(zh)
|
2009-07-13 |
2017-09-11 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US11571431B2
(en)
|
2013-12-04 |
2023-02-07 |
Galmed Research And Development Ltd |
Aramchol salts
|
|
SG10201801654RA
(en)
|
2014-05-28 |
2018-04-27 |
Childrens Hospital Med Ct |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
AU2015331848B2
(en)
|
2014-10-17 |
2022-03-03 |
Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
PL3456717T3
(pl)
|
2015-07-06 |
2021-10-25 |
Gilead Sciences, Inc. |
Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
|
|
EA201890949A1
(ru)
|
2015-11-25 |
2018-12-28 |
Джилид Аполло, Ллс |
СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
|
|
AU2016361412A1
(en)
*
|
2015-11-25 |
2018-05-24 |
Gilead Apollo, Llc |
Pyrazole ACC inhibitors and uses thereof
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
SG11201807077RA
(en)
|
2016-03-02 |
2018-09-27 |
Gilead Apollo Llc |
Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
|
|
CN109415685B
(zh)
|
2016-05-05 |
2023-07-04 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
EP4553082A3
(en)
|
2016-11-04 |
2025-08-20 |
Children's Hospital Medical Center |
Liver organoid compositions and methods of making and using same
|
|
JP2019537607A
(ja)
*
|
2016-11-10 |
2019-12-26 |
ガルメド リサーチ アンド ディベロップメント リミテッド |
非アルコール性脂肪性肝疾患の患者における線維化の抑制
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
CA3043284C
(en)
*
|
2016-11-10 |
2022-06-28 |
Galmed Research And Development Ltd. |
Treatment for fibrosis
|
|
EP3548507A4
(en)
|
2016-12-05 |
2020-07-15 |
Children's Hospital Medical Center |
COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
|
|
ES2928773T3
(es)
|
2017-01-17 |
2022-11-22 |
Heparegenix Gmbh |
Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
|
|
EP3571205B1
(en)
*
|
2017-01-22 |
2023-08-30 |
Sunshine Lake Pharma Co., Ltd. |
Thienopyrimidine derivative and use thereof in medicine
|
|
US11142531B2
(en)
|
2017-03-24 |
2021-10-12 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
|
|
JP2020512342A
(ja)
*
|
2017-03-28 |
2020-04-23 |
ギリアード サイエンシーズ， インコーポレイテッド |
肝疾患を処置する方法
|
|
SI4122464T1
(sl)
*
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
JP2020516627A
(ja)
*
|
2017-04-12 |
2020-06-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
肝疾患を処置する方法
|
|
JP7248586B2
(ja)
|
2017-04-14 |
2023-03-29 |
チルドレンズ ホスピタル メディカル センター |
複数ドナー幹細胞組成物およびそれを作製する方法
|
|
JP7266531B2
(ja)
*
|
2017-04-18 |
2023-04-28 |
ジェンフィ |
エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
|
|
US11583570B2
(en)
*
|
2017-04-24 |
2023-02-21 |
Tsinghua University |
Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
|
|
US20200129511A1
(en)
*
|
2017-06-19 |
2020-04-30 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of nafld and nash
|
|
CN111201234A
(zh)
*
|
2017-07-17 |
2020-05-26 |
南京瑞捷医药科技有限公司 |
新型化合物及其作为acc抑制剂的用途
|
|
TW201910338A
(zh)
*
|
2017-07-26 |
2019-03-16 |
大陸商南京聖和藥業股份有限公司 |
作為acc抑制劑的化合物及其應用
|
|
CN109316601B
(zh)
*
|
2017-07-31 |
2021-11-09 |
武汉朗来科技发展有限公司 |
药物组合物及其用途
|
|
JP2020532551A
(ja)
|
2017-09-03 |
2020-11-12 |
アンジオン バイオメディカ コーポレーション |
Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
|
|
US11033601B2
(en)
*
|
2017-09-14 |
2021-06-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Selective inhibition of V1b for treating fatty liver
|
|
US10980810B2
(en)
*
|
2017-10-06 |
2021-04-20 |
Gilead Sciences, Inc. |
Combination therapy comprising an ACC inhibitor
|
|
EP3694603B1
(en)
|
2017-10-10 |
2026-04-08 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
US11419918B2
(en)
*
|
2017-11-06 |
2022-08-23 |
Shenzhen Turier Biotech Co., Ltd. |
Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
|
|
CN107693514A
(zh)
*
|
2017-12-04 |
2018-02-16 |
威海贯标信息科技有限公司 |
一种鲁格列净组合物
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
NZ766594A
(en)
|
2018-01-31 |
2025-12-19 |
Heparegenix Gmbh |
Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
CN111989103A
(zh)
*
|
2018-04-17 |
2020-11-24 |
勃林格殷格翰国际有限公司 |
药物组合物、其治疗方法和用途
|
|
WO2019209738A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Ph Pharma Co., Ltd. |
Use of neutrophil elastase inhibitors in liver disease
|
|
EP3810139A1
(en)
|
2018-06-21 |
2021-04-28 |
HepaRegeniX GmbH |
Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
IL279641B2
(en)
|
2018-07-16 |
2024-04-01 |
Heparegenix Gmbh |
Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
|
|
EP4678727A3
(en)
|
2018-07-26 |
2026-03-11 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
JP2022514731A
(ja)
*
|
2018-08-14 |
2022-02-15 |
アヴォリント |
原発性硬化性胆管炎の処置方法
|
|
US11254660B2
(en)
|
2018-08-31 |
2022-02-22 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
|
CA3111025C
(en)
*
|
2018-09-06 |
2023-10-31 |
Galmed Research And Development Ltd |
Combination therapy for the treatment of liver disease
|
|
CA3112026A1
(en)
|
2018-09-12 |
2020-03-19 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
CN110950884B
(zh)
*
|
2018-09-27 |
2024-03-26 |
上海翰森生物医药科技有限公司 |
含二并环类衍生物抑制剂、其制备方法和应用
|
|
US20220041616A1
(en)
*
|
2018-11-20 |
2022-02-10 |
The National Institutes of Pharmaceutical R&D Co., Ltd. |
Spiro compound and medical uses thereof
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
US12600943B2
(en)
|
2019-02-01 |
2026-04-14 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
JP7631217B2
(ja)
*
|
2019-04-10 |
2025-02-18 |
ジェンフィット |
式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
|
|
KR20220017917A
(ko)
|
2019-05-08 |
2022-02-14 |
알리고스 테라퓨틱스 인코포레이티드 |
Thr-베타의 조절제 및 이의 사용 방법
|
|
US12497597B2
(en)
|
2019-05-31 |
2025-12-16 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
AU2020283048A1
(en)
|
2019-05-31 |
2021-12-23 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
TWI770527B
(zh)
|
2019-06-14 |
2022-07-11 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
|
EP3995498A4
(en)
*
|
2019-07-02 |
2023-03-01 |
Sunshine Lake Pharma Co., Ltd. |
THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
|
|
BR112022001488A2
(pt)
|
2019-07-29 |
2022-04-19 |
Heparegenix Gmbh |
Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos
|
|
AR119594A1
(es)
|
2019-08-09 |
2021-12-29 |
Gilead Sciences Inc |
Derivados de tienopirimidina como inhibidores acc y usos de los mismos
|
|
CN110628810B
(zh)
*
|
2019-08-13 |
2022-06-28 |
浙江大学 |
一种提高植物光合效率的方法
|
|
WO2021040440A1
(ko)
*
|
2019-08-30 |
2021-03-04 |
(주)셀트리온 |
비알콜성 지방간염(nash, nonalcoholic steatohepatitis) 치료 또는 예방을 위한 약학 조성물
|
|
US20230105984A1
(en)
|
2019-12-23 |
2023-04-06 |
Svetlana Marukian |
Compositions and methods for the treatment of liver diseases and disorders
|
|
CA3164361A1
(en)
|
2020-01-15 |
2021-07-22 |
Heparegenix Gmbh |
3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
|
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
|
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
|
|
CA3168474A1
(en)
*
|
2020-03-11 |
2021-09-16 |
Mi-Kyung Kim |
Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis
|
|
CA3175541A1
(en)
|
2020-03-30 |
2021-10-07 |
Gilead Sciences, Inc. |
Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
|
|
JP7446475B2
(ja)
|
2020-04-02 |
2024-03-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｏｔ阻害剤化合物を調製するためのプロセス
|
|
CN111407892A
(zh)
*
|
2020-04-08 |
2020-07-14 |
中国药科大学 |
Acsl4及其在nash中的应用
|
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
|
EP4154880A4
(en)
*
|
2020-05-21 |
2024-06-05 |
Shionogi & Co., Ltd |
Pharmaceutical for treating fatty liver diseases
|
|
EP4000616A1
(en)
*
|
2020-11-17 |
2022-05-25 |
Inventiva |
Combination therapy for the treatment of a liver disease
|
|
WO2022192428A1
(en)
|
2021-03-11 |
2022-09-15 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
EP4681774A3
(en)
|
2021-03-29 |
2026-03-25 |
Gilead Sciences, Inc. |
Khk inhibitors
|
|
TW202345826A
(zh)
*
|
2021-06-04 |
2023-12-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
|
|
WO2023034381A1
(en)
*
|
2021-08-31 |
2023-03-09 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Quantitative systems pharmacology methods for identifying therapeutics for disease states
|
|
WO2023047203A1
(en)
*
|
2021-09-25 |
2023-03-30 |
Torrent Pharmaceuticals Ltd |
Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
|
|
JPWO2023090411A1
(https=)
|
2021-11-19 |
2023-05-25 |
|
|
|
EP4731212A1
(en)
*
|
2023-06-20 |
2026-04-29 |
Sagimet Biosciences Inc. |
Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
|
|
WO2025225969A1
(ko)
*
|
2024-04-22 |
2025-10-30 |
연세대학교 원주산학협력단 |
CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법
|